In renal cell carcinoma, RRM2 silencing can increase renal cell carcinoma’s sensitivity to sunitinib, as well as improving the anti-tumor efficacy of PD-L1 blockade [11]. Here, RRM2 is linked to hereditary clear cell renal cell carcinoma.